University of Washington
This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.
OUTLINE: Patients are assigned to 1 of 3 groups. GROUP I: Patients for whom initial fluciclovine or PSMA PET/CT does not reveal any abnormalities outside the prostatic fossa undergo PSA rechecks every 3 months, and undergo fluciclovine or PSMA PET/CT once PSA is \> 2 ng/ml. If still no abnormalities are found outside of the prostatic fossa, patients continue to undergo PSA rechecks every 3 months, and undergo fluciclovine or PSMA PET/CT once PSA is \> 5 ng/ml. Patients are off study for treatment plan once PSA reaches 10 ng/ml. GROUP II: Patients undergo fluciclovine or PSMA PET/CT and who h…
Inclusion Criteria: * Patient must have histologically or cytologically documented evidence of prostate adenocarcinoma * Patient must previously have undergone radical prostatectomy * Patient must previously have undergone either adjuvant or salvage radiation therapy to the prostatic fossa +/- whole pelvis * Patient must have a prostate specific antigen (PSA) \>= 0.2 and \< 10 ng/mL. If there is only one PSA value that has risen to \>= 0.2 with this biochemical recurrence, a second PSA value must be confirmed to be within \>= 0.2 and \< 10 ng/mL at least 2 weeks from the first value and withi…
Undergo fluciclovine PET/CT
Undergo lymphadenectomy
Undergo radiation therapy
Given PO
Given PO
Undergo fluciclovine PET/CT
Given PO
Undergo PSMA PET scan
Arctuva estimate
Verify or correct the compensation shown for this listing.